Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a prospective study, 93 patients were observed up to nine months after open-heart surgery using hypothermia, hemodilution and cold cardioplegia. In the first two weeks frequent determinations were made of serum aminotransferase, alkaline phosphatases (ALP), lactic dehydrogenase isoenzymes, gamma glutamyltransferase (GT), total and free bilirubin and bile acids. Plasma hemoglobin was measured at the end of the operation. After the first period, aminotransferases, alkaline phosphatases and bilirubin were determined monthly. On the first postoperative day almost all of the patients showed abnormal aspartate aminotransferase (ASAT) activity and ASAT/ALAT (alanine aminotransferase) greater than 1, and about 25% had hyperbilirubinemia. The findings suggested early postoperative leakage of enzymes not only from the myocardium, but also from the liver. After two weeks the patients presented another pattern of liver dysfunction, with abnormal ALAT in 50%, ASAT/ALAT less than 1, and abnormal ALP and GT in 28 and 45%, respectively. Eight patients were judged to have post-transfusion hepatitis of non-A, non-B type. Six of them had abnormal aminotransferases for more than six months.
Scand J Thorac Cardiovasc Surg 1984
PMID:Hepatic dysfunction after open-heart surgery. 615 78

In a prospective study on the causes and frequency of hepatitis after operations on the open heart, two homogeneous groups of patients were formed. In one of them, the amount of homologous blood was reduced to half by means of preoperative donations of autologous blood, the total blood requirement remaining the same. Hepatitis occurred postoperatively in 10% of the cases. The factors which gave rise to the hepatitis were large-pool clotting preparations, transfusion with homologous blood and cross-infection in the hospital. Even after exclusion of other risk factors, the frequency of hepatitis among the recipients of coagulation preparations was around 60%. The frequency of the cases of hepatitis due to foreign blood was about 5 per 100 patients or about 1 per 100 units of blood. By use of autologous blood collected preoperatively, the risk due to transfusion could be lowered by 50%. In polytransfusion, a disproportionately high rise in the risk of hepatitis was observed. It is probably to be ascribed to unknown factors in the hospital environment ("nosocomial hepatitis").
Thorac Cardiovasc Surg 1980 Feb
PMID:Hepatitis after cardiosurgery. Frequency and causes. Results of a prospective study with use of autologous blood. 615 28

A successful program to reduce the amount of blood required in cardiac surgical procedures should encompass all phases of surgical therapy: preoperative exclusion or treatment of coagulation disturbances, intraoperative hemodilution to a hematocrit of 20% and subsequent reinfusion of autologous blood, and postoperative reinfusion of shed mediastinal blood during the first 12 postoperative hours keeping the hematocrit at 28%. In 1977, the bank blood requirement for 527 cardiac surgical procedures (control group) averaged 2 units per patient. Twenty-seven percent could be operated on without bank blood. Intraoperative hemodilution was applied lowering the hematocrit to 23%. The postoperative limit for blood transfusion was a hemoglobin of 11 g/100 ml or a hematocrit of 32%. The reinfusion of shed mediastinal blood, introduced in 1978 (512 patients), has reduced the need for bank blood by 50% to one unit per patient (p less than 0.001). Fifty-three percent of the patients required no bank blood. Since mid-1980 (350 patients), postoperative hemodilution has reduced the need for bank blood to 0.3 units per patient (p less than 0.001). Eighty percent of the operations could be carried out without bank blood. The postoperative blood loss of 1.4 units per patient was identical in both the control and reinfusion groups. This reduction of homologous blood transfusions results in a decreased risk of hepatitis for the patient and in a financial advantage for the hospital.
Thorac Cardiovasc Surg 1982 Jun
PMID:Reduction of bank blood requirements in cardiac surgery. 618 May 7

Although amiodarone is the most effective antiarrhythmic agent for maintaining sinus rhythm in patients with atrial fibrillation, it is generally used as the drug of the last resort in the United States. This is because long-term amiodarone therapy can potentially cause serious noncardiac side effects, such as pulmonary fibrosis, thyroid dysfunction, hepatitis, and neurotoxicity. Furthermore, it may also cause adverse interaction with digoxin, coumadin, and other antiarrhythmic drugs. Atrial fibrillation is frequently associated with a variety of cardiac disease, and its triggering factors vary among patients. Treatment strategy should be tailored to each individual patient according to the clinical presentation, concomitant disease, left ventricular function, and response (efficacy and side effects) to each drug regimen.
Cardiovasc Drugs Ther 1994 Oct
PMID:Low-dose amiodarone should not be the first-line treatment for atrial fibrillation. 787 76

Traditional centrally acting antihypertensives have been associated with a high incidence of adverse effects and are no longer recommended as first-line therapy. The newer imidazoline receptor agonists must overcome this reputation if they are to gain recognition as potential first-line agents for hypertension. Methyldopa, a centrally acting alpha(2)-agonist, is characterized by a number of serious adverse reactions that limit its use. Although unpredictable idiosyncratic or hypersensitivity reactions are uncommon, these include hepatitis, myocarditis, and hemolytic anaemia. Less serious problems such as abnormal liver function tests, positive Coombs test, drug-induced fever, and pancreatitis also occur. Central side effects include drowsiness, fatigue, lethargy, sedation, depression, psychotic reactions, nasal stuffiness, impotence, and exacerbation of Parkinsonism. In hypertensive men, methyldopa is less well tolerated than either captopril or propranolol, and up to 20% of patients discontinue therapy because of adverse effects. Clonidine acts primarily as an alpha(2)-agonist but also acts as an agonist at imidazoline receptors in the rostroventrolateral medulla. It is equipotent to most other antihypertensives but is considerably less well-tolerated in comparative trials. The principal adverse effects of clonidine are drowsiness, sedation, lethargy and dry mouth. Reserpine acts primarily by depleting central catecholamine neurotransmitter stores. It was very extensively used in early hypertension trials, but its central side effects of sedation, nasal stuffiness, and severe depression are now considered so undesirable that the drug is seldom prescribed. The imidazoline (I1) agonists moxonidine and rilmenidine act selectively and have very little central alpha(2)-agonist activity. In comparative studies against placebo and other reference antihypertensives, the only adverse effect consistently associated with these drugs was dry mouth (approximate placebo-corrected incidence 10%). Sedation was not pronounced. Withdrawal syndromes are complex pathophysiologic processes and occur with a variety of antihypertensive drugs. Cessation of therapy with clonidine and, to a lesser extent, methyldopa may result in a severe withdrawal syndrome characterized by restlessness, sweating, anxiety, tremor, palpitations, and headache. There may be a rapid rise in blood pressure, often with a true "rebound" to higher than pretreatment levels. Plasma and urinary catecholamine levels are increased, and fatalities have been reported. It is important to stress that such a syndrome has not been recorded, in animal or human studies, with either moxonidine or rilmenidine.
J Cardiovasc Pharmacol 1996
PMID:Aspects of tolerability of centrally acting antihypertensive drugs. 887 99

Lipoma in the ventricular septum is very rare. Our review of the English literature revealed that our case is the sixth of removal of lipoma in the ventricular septum. A 60-year-old male was admitted because a mass in the ventricular septum was found incidentally in abdominal CT taken following type B hepatitis. CT scanning of the heart showed 2 cm diameter of tumor in the ventricular septum. The tumor had very low radiodensity, so it was thought to be identical to fat tissue. The tumor was more clearly visualized by MR imaging and the signal intensity was high on the T1-weighted image. The tumor was suspected to be lipoma. The intraoperative histological diagnosis showed the tumor was lipoma. The tumor adhered strictly on the myocardium of the septum, and it was located near the left anterior descending coronary artery. It could not completely resected, in these reasons. Postoperative course was uneventful, and echocardiogram taken 9 months after the operation showed no evidence of enlargement of the residual tumor. It is necessary to follow-up rigidly for the potential of enlargement of the residual tumor.
Jpn J Thorac Cardiovasc Surg 1998 Oct
PMID:[A case of cardiac lipoma in the ventricular septum]. 984 89

Since the first deliberate open heart operation was performed on a patient known to be carrying HIV, much has been learned. The fear that cardiopulmonary bypass might cause acceleration of the disease has not been borne out. Patients infected with HIV have shown considerable tolerance to major cardiac and pulmonary surgery. Indeed, the extraordinary fruits of a massive research effort have made it reasonable to perform elective surgery and to offer major surgery to patients with the full-blown syndrome of AIDS. The concern that the operators would be exposed to significant risk of acquiring the infection during surgery has proved to be unfounded. This has been in part due to the widespread adoption of universal precautions against the passage of microorganisms from patient to operator. However, there remain surgeons who ignore these precautions. The price they pay is the risk of acquiring hepatitis, which is far more easily transmitted than AIDS and may be fatal.
Semin Thorac Cardiovasc Surg 2000 Apr
PMID:Cardiac surgery and the human immunodeficiency virus. 1080 37

Fibrin sealants are prepared from fibrinogen, thrombin and sometimes also factor XIII that have been purified from human plasma. Bovine aprotinin is also included in some preparations. Each of these components has the potential to carry blood-borne pathogens, albeit at a very low frequency. In order to minimize the risk of viral transmission from commercial fibrin sealants, plasma donations undergo a series of procedures that contribute to avoiding, inactivating and eliminating potential contaminants. The procedures for selection and screening of plasma donors, and the testing of donated plasma, incorporates highly sensitive molecular techniques (e.g. PCR testing) and contributes significantly to reducing the theoretical possibility of viral transmission. The starting material for bovine aprotinin is also carefully selected, and the manufacturing process rigorously assessed, to minimize the putative risk of transmission of bovine spongiform encephalopathies. The manufacturing process for commercial fibrin sealants comprises a range of procedures, including heat treatment (e.g. pasteurization, dry or vapor heating), filtration, solvent/detergent treatment, precipitation, pH treatment and chromatography. Some steps are an inherent part of the purification process and others (e.g. pasteurization, nanofiltration) are deliberately introduced to inactivate/eliminate potential pathogens. Current manufacturing processes provide a very high degree of safety for fibrin sealants. In 20 years of worldwide use, there have been no known cases of hepatitis or HIV transmission associated with the use of commercial fibrin sealants.
Cardiovasc Surg 2003 Aug
PMID:The safety of fibrin sealants. 1286 85

Interferons (IFNs) display pleiotropic properties; not only do they protect cells from viral infections but they may also modulate cell growth and differentiation as well as innate and adaptive immune responses. Therapeutic applications of IFNs have proven efficacy in a variety of illnesses, including hepatitis, multiple sclerosis, and some forms of cancer. Emerging evidence has been obtained during recent years that interferons impact on molecular and cellular mechanisms implicated in the development of vascular proliferative diseases such as atherosclerosis, restenosis, and cardiac allograft vasculopathy. Further appreciation and delineation of the precise mechanisms on how interferons influence vascular proliferative disease processes could potentially facilitate the development of novel treatment options attenuating these common causes of cardiovascular morbidity and mortality.
Cardiovasc Res 2005 Jun 01
PMID:Interference by interferons: Janus faces in vascular proliferative diseases. 1591 8

A 73-year-old man with hepatitis-C-related cirrhosis and an elevated alpha-fetoprotein level and tumor in segment 3 of his liver was referred for interventional radiologic treatment. He was not a candidate for surgical resection due to impaired liver function and his personal preferences. On conventional ultrasonography no lesion could be detected, but the tumor was clearly depicted by intra-arterial carbon-dioxide-enhanced ultrasonography. Radiofrequency ablation was performed safely and accurately under the guidance of carbon-dioxide-enhanced ultrasonography. By concomitant performance of transcatheter arterial chemoembolization with radiofrequency ablation, extensive necrosis was obtained and adequate tumor volume reduction achieved with only one treatment session.
Cardiovasc Intervent Radiol
PMID:Use of intra-arterial carbon-dioxide-enhanced ultrasonography for guidance of radiofrequency ablation and transcatheter arterial chemoembolization in hepatocellular carcinoma. 1693 61


<< Previous 1 2 3 Next >>